BNP/CALL/ASTRAZENECA/13000/0.1/20.12.24 Stock

DE000PC3BUY8

Market Closed - Boerse Frankfurt Warrants 11:21:11 2024-06-07 EDT
0.98 ^EUR	-1.01%

Current month	+24.05%
1 month	+22.50%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart ASTRAZENECA PLC

Chart BNP/CALL/ASTRAZENECA/13000/0.1/20.12.24

Latest news about ASTRAZENECA PLC

I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer	06-07	AQ
ASTRAZENECA : JP Morgan reiterates its Buy rating	06-07	ZD
Pharma Company Astrazeneca Withdrawing Covid Vaccine Because It's Outdated - Not 'After Admitting to Dangerous Side Effect'	06-06	AQ
Astrazeneca completes £1.5bn Fusion Pharmaceuticals deal	06-06	AQ

More news

Quotes 5-day view

Date	Price	Change
24-06-07	0.98	-1.01%
24-06-06	0.99	0.00%
24-06-05	0.99	+10.00%
24-06-04	0.9	+2.27%
24-06-03	0.88	+11.39%

Real-time Boerse Frankfurt Warrants

Last update June 07, 2024 at 11:21 am

More quotes

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	ASTRAZENECA PLC
Issuer	BNP Paribas
WKN	PC3BUY
ISIN	DE000PC3BUY8
Date issued	2024-01-16
Strike	13,000 p
Maturity	2024-12-20 (195 Days)
Parity	10 : 1
Emission price	0.31 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	1 €
Lowest since issue	0.09 €
Spread	0.01 €
Spread %	1.00%

Company Profile

AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows: - product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases); - collaboration revenue (4.4%). Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).

Sector

More about the company